The only inhibitor identified to promote stable disease or tumor regression across all AM models was Lenvatinib, a multiple receptor tyrosine kinase (RTK) inhibitor that is most potent against the VEGFR and FGFR families [20, 21]. Here, NTRK1 is linked to neoplasm.